<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-110343</identifier>
<setSpec>1699-258X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Biosimilar drugs in Mexico: Position of the Mexican College of Rheumatology, 2012</dc:title>
<dc:description xml:lang="en">Biotechnological drugs (BTDs) are complex molecules whose manufacturing process precludes the ability to identically reproduce the structure of the original product, and therefore there cannot be an absolute equivalence between the original (innovative) medication and its biosimilar counterpart. BTDs have been proven useful in the treatment of several rheumatic diseases, however their high cost has prevented their use in many patients. Several BTD patents have expired or are close to expire, triggering the development of structurally similar drugs with efficacy and safety profiles comparable to the innovative compound; however, these must be evaluated through evidence based medicine. The Mexican General Health Law contemplates the registry of these biosimilar drugs for their use in our country. This document is a forethought from members of the Mexican College of Rheumatology, pharmacologists, and epidemiologists, in accordance with Mexican health authorities regarding the necessary scientific evidence required to evaluate the efficacy and safety of biosimilar drugs before and after their arrival to the Mexican market(AU)</dc:description>
<dc:creator>Medrano Ramírez, Gabriel</dc:creator>
<dc:creator>Díaz Borjó, Alejandro</dc:creator>
<dc:creator>Cardiel Ríos, Mario Humberto</dc:creator>
<dc:creator>Díaz Jouanen, Efraín</dc:creator>
<dc:creator>Espinosa Morales, Rolando</dc:creator>
<dc:creator>Fraga Mouret, Antonio</dc:creator>
<dc:creator>Barreira Mercado, Eduardo Rubén</dc:creator>
<dc:creator>Talavera Piña, Juan Osvaldo</dc:creator>
<dc:creator>Muñoz Barradas, Francisco José</dc:creator>
<dc:creator>Garza Elizondo, Mario Alberto</dc:creator>
<dc:creator>Vera Lastra, Olga Lidia</dc:creator>
<dc:creator>Barile Fabris, Leonor Adriana</dc:creator>
<dc:creator>Arce Salinas, César Alejandro</dc:creator>
<dc:creator>Flores Murrieta, Francisco Javier</dc:creator>
<dc:creator>Esquivel Valerio, Jorge Antonio</dc:creator>
<dc:creator>Luján Estrada, Miguel</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los medicamentos biotecnológicos (MBT) son moléculas complejas cuyo proceso de elaboración impide replicar con gran exactitud la sustancia original, por lo que no existe una equivalencia absoluta entre el fármaco original (innovador) y el biocomparable. Los MBT han probado su eficacia en diversas afecciones reumáticas, aunque su alto coste impide su utilización en muchos pacientes. Diversas patentes de medicamentos biotecnológicos han expirado o expirarán próximamente, detonando así el desarrollo de fármacos estructuralmente similares y probablemente con eficacia y seguridad comparable a los medicamentos innovadores, aunque estas características deben ser probadas. La Ley General de Salud Mexicana actual contempla el registro de estos medicamentos para su utilización en nuestro país. Este documento es una reflexión de miembros del Colegio Mexicano de Reumatología, farmacólogos e investigadores en epidemiología, en conjunción con nuestras autoridades sanitarias, sobre los estudios científicos necesarios de los biocomparables previos y posterior a su incursión en el mercado mexicano(AU)</dc:description>
<dc:source>Reumatol. clín. (Barc.);9(2): 113-116, mar.-abr.2013.</dc:source>
<dc:identifier>ibc-110343</dc:identifier>
<dc:title xml:lang="es">Medicamentos biocomparables en México: la postura del Colegio Mexicano de Reumatología, 2012</dc:title>
<dc:subject>^d8990^s22080</dc:subject>
<dc:subject>^d54726</dc:subject>
<dc:subject>^d23478</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d13427^s22041</dc:subject>
<dc:subject>^d12630^s22048</dc:subject>
<dc:subject>^d13339^s22041</dc:subject>
<dc:subject>^d13339^s37748</dc:subject>
<dc:subject>^d27938^s22073</dc:subject>
<dc:subject>^d12630^s22049</dc:subject>
<dc:subject>^d33150^s22045</dc:subject>
<dc:subject>^d13427^s37748</dc:subject>
<dc:subject>^d12630^s22019</dc:subject>
<dc:subject>^d13427^s22049</dc:subject>
<dc:type>article</dc:type>
<dc:date>201304</dc:date>
</metadata>
</record>
</ibecs-document>
